Zacks Research Issues Positive Forecast for A Earnings

Agilent Technologies, Inc. (NYSE:A) – Research analysts at Zacks Research upped their Q1 2026 EPS estimates for shares of Agilent Technologies in a note issued to investors on Wednesday, March 19th. Zacks Research analyst R. Department now anticipates that the medical research company will post earnings of $1.39 per share for the quarter, up from their prior forecast of $1.35. The consensus estimate for Agilent Technologies’ current full-year earnings is $5.57 per share. Zacks Research also issued estimates for Agilent Technologies’ Q2 2026 earnings at $1.47 EPS.

Agilent Technologies (NYSE:A) last posted its quarterly earnings results on Wednesday, February 26th. The medical research company reported $1.31 EPS for the quarter, beating analysts’ consensus estimates of $1.27 by $0.04. The business had revenue of $1.68 billion during the quarter, compared to the consensus estimate of $1.67 billion. Agilent Technologies had a return on equity of 25.56% and a net margin of 19.27%.

Other research analysts have also recently issued research reports about the company. Robert W. Baird decreased their target price on Agilent Technologies from $161.00 to $159.00 and set an “outperform” rating on the stock in a research report on Thursday, February 27th. JPMorgan Chase & Co. lowered their price objective on shares of Agilent Technologies from $165.00 to $160.00 and set an “overweight” rating for the company in a research report on Tuesday, November 26th. Sanford C. Bernstein cut their target price on shares of Agilent Technologies from $140.00 to $135.00 and set a “market perform” rating on the stock in a research report on Tuesday, November 26th. Wells Fargo & Company lowered their price target on shares of Agilent Technologies from $157.00 to $155.00 and set an “overweight” rating for the company in a report on Monday, December 9th. Finally, StockNews.com raised Agilent Technologies from a “hold” rating to a “buy” rating in a report on Tuesday, December 24th. Seven analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $146.15.

Agilent Technologies Stock Performance

Shares of NYSE:A opened at $120.35 on Monday. Agilent Technologies has a 1 year low of $117.17 and a 1 year high of $155.35. The stock has a market capitalization of $34.31 billion, a price-to-earnings ratio of 27.67, a price-to-earnings-growth ratio of 3.39 and a beta of 1.11. The company has a debt-to-equity ratio of 0.56, a current ratio of 2.20 and a quick ratio of 1.66. The company’s 50 day simple moving average is $135.88 and its 200 day simple moving average is $137.05.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. State Street Corp lifted its stake in shares of Agilent Technologies by 1.2% in the third quarter. State Street Corp now owns 12,819,897 shares of the medical research company’s stock valued at $1,903,498,000 after buying an additional 158,175 shares in the last quarter. Wellington Management Group LLP lifted its position in Agilent Technologies by 0.6% in the 4th quarter. Wellington Management Group LLP now owns 9,306,805 shares of the medical research company’s stock valued at $1,250,276,000 after acquiring an additional 59,781 shares in the last quarter. Geode Capital Management LLC boosted its stake in Agilent Technologies by 0.8% during the 4th quarter. Geode Capital Management LLC now owns 7,002,671 shares of the medical research company’s stock valued at $938,291,000 after purchasing an additional 53,992 shares during the last quarter. Pictet Asset Management Holding SA increased its holdings in Agilent Technologies by 0.9% during the 4th quarter. Pictet Asset Management Holding SA now owns 5,213,739 shares of the medical research company’s stock worth $700,414,000 after purchasing an additional 47,495 shares in the last quarter. Finally, Deutsche Bank AG raised its stake in shares of Agilent Technologies by 0.9% in the fourth quarter. Deutsche Bank AG now owns 4,436,700 shares of the medical research company’s stock worth $596,026,000 after purchasing an additional 38,348 shares during the last quarter.

Insiders Place Their Bets

In related news, VP Rodney Gonsalves sold 1,908 shares of the firm’s stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $121.98, for a total transaction of $232,737.84. Following the completion of the sale, the vice president now owns 21,786 shares of the company’s stock, valued at $2,657,456.28. This trade represents a 8.05 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Padraig Mcdonnell sold 1,911 shares of the business’s stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $150.00, for a total value of $286,650.00. Following the completion of the transaction, the chief executive officer now directly owns 39,652 shares in the company, valued at approximately $5,947,800. This trade represents a 4.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here.

Agilent Technologies Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, April 23rd. Shareholders of record on Tuesday, April 1st will be given a dividend of $0.248 per share. This represents a $0.99 dividend on an annualized basis and a yield of 0.82%. The ex-dividend date of this dividend is Tuesday, April 1st. Agilent Technologies’s dividend payout ratio is presently 22.76%.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.